Pfizer Inc. (NYSE: PFE) cited adverse reactions for suspending studies of its osteoarthritis treatment tanezumab. The stock price fell 42 cents to close at $14.46.
Pfizer Halts Osteoarthritis Drug Study
June 24, 2010 at 17:04 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.